Mesa Laboratories Acquires Gyros Protein Technologies
October 31, 2019
Mesa Laboratories (NASDAQ: MLAB) acquired Gyros Protein Technologies Holding AB (GPT) from AP6 (Sixth Swedish National Pension Fund), Ampersand Capital Partners and individual shareholders for $180 million in cash. The acquisition, which establishes Mesa's new Biopharmaceutical Development platform, adds GPT's immunoassay and peptide synthesis instruments and consumables and is expected to contribute roughly $37–$40 million of revenue in the first 12 months (about 55% recurring).
- Buyers
- Mesa Laboratories, Inc.
- Targets
- Gyros Protein Technologies Holding AB
- Sellers
- AP6 (Sixth Swedish National Pension Fund), Ampersand Capital Partners, Various individual shareholders
- Industry
- Biotechnology
- Location
- Uppsala County, Sweden
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Grain & Protein Technologies Acquires Munters FoodTech Equipment
June 3, 2025
Manufacturing
Grain & Protein Technologies (GPT) has completed the acquisition of Munters FoodTech Equipment, the business that sells and services the Aerotech, Euroemme, and Reventa branded products. The deal brings approximately 400 Munters FoodTech Equipment employees into GPT and expands GPT's product portfolio and capabilities in climate control and air treatment for the protein and agribusiness segments.
-
Gilead Sciences Acquires MiroBio
September 20, 2022
Biotechnology
Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.
-
Mesa Laboratories Acquires Agena Bioscience
September 14, 2021
Medical Devices
Mesa Laboratories, Inc. (NASDAQ:MLAB) entered into a definitive agreement to acquire Agena Bioscience, Inc. for $300 million in cash. Agena, a San Diego–based molecular diagnostics and genomics tools company, is expected to add roughly $63–67 million of revenue (about 65% recurring) in the first 12 months and will form Mesa’s new Clinical Genomics Division.
-
Arcline Investment Management Acquires Polypeptide Therapeutic Solutions (PTS)
April 27, 2021
Biotechnology
Arcline Investment Management, a growth-oriented private equity firm, has acquired Polypeptide Therapeutic Solutions, S.L. (PTS) from Columbus Venture Partners. PTS is a Valencia-based GMP CDMO specializing in polyamino-acid (PAA) nanoparticle encapsulation and related drug-delivery services; Arcline plans to scale GMP production and expand the company's technology portfolio to support mRNA, gene/cell therapies, biologics and vaccines.
-
Cole-Parmer (GTCR Portfolio) Acquires ZeptoMetrix
January 12, 2021
Biotechnology
GTCR’s portfolio company Cole-Parmer has acquired ZeptoMetrix, a Buffalo-based developer and manufacturer of quality control standards and verification panels for molecular diagnostic testing. The acquisition expands Cole-Parmer’s life sciences quality controls and reference standards portfolio and strengthens its capabilities in infectious disease and molecular diagnostics.
-
MLM Medical Labs Acquires MD Biosciences, Inc.
October 27, 2020
Healthcare Services
MLM Medical Labs, a Great Point Partners portfolio company, has acquired MD Biosciences, Inc., an Oakdale, Minnesota-based provider of preclinical, translational and clinical-phase contract research services. The deal expands MLM's U.S. footprint and adds immunohistochemistry, preclinical research and histopathology capabilities to its global laboratory platform as part of an integration with recent U.S. additions such as CirQuest Labs.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.